Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar

Objectives: Myasthenia gravis (MG) is an immune-mediated neuromuscular disorder responsive to immunomodulatory treatments. 10–20% of MGs are not responsive to conventional first-line therapies. Here, we sought to investigate the efficacy and safety of rituximab therapy in the treatment of patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Fatehi, Farzad, Moradi, Kamyar, Okhovat, Ali Asghar, Shojatalab, Ghazaleh, Sedighi, Behnaz, Boostani, Reza, Sarraf, Payam, Haghi Ashtiani, Bahram, Ghasemi, Majid, Moussavi, Soussan, Anjidani, Nassim, Nafissi, Shahriar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427762/
https://www.ncbi.nlm.nih.gov/pubmed/34512504
http://dx.doi.org/10.3389/fneur.2021.682622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427762/
https://www.ncbi.nlm.nih.gov/pubmed/34512504
http://dx.doi.org/10.3389/fneur.2021.682622

Ejemplares similares